The company announced dose administration of the first patient in a Phase 2A clinical trial of SUVN-502, a 5HT6 antagonist in patients with moderate Alzheimer’s Disease (AD).
| Subscribe To Our Free Newsletter |
The Most Valuable Commodity Is Information!
